D. Scott McMeekin

7.6k citations

121 papers · 5.6k indexed · 3 hit papers · h-index 40

Obstetrics and Gynecology top 0.05%
- Endometrial and Cervical Cancer Treatments 73
- Uterine Myomas and Treatments 13
Reproductive Medicine top 0.1%
- Ovarian cancer diagnosis and treatment 69
- Endometriosis Research and Treatment 19
Oncology top 2%
Cancer Research top 5%
Pathology and Forensic Medicine top 2%
Epidemiology
- Cervical Cancer and HPV Research 15
Surgery
- Intraperitoneal and Appendiceal Malignancies 14
- Colorectal and Anal Carcinomas 8
Genetics
- Estrogen and related hormone effects 8

Co-authors: Michael W. Sill Paul DiSilvestro J Bénda David E. Cohn Joan L. Walker Robert S. Mannel Kathleen N. Moore Michael A. Gold
Cited by: Obstetrics and Gynecology Reproductive Medicine Oncology
Journals: Journal of Clinical Oncology (21 papers)JNCI Journal of the National Cancer Institute (2 papers)Cancer (4 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

D. Scott McMeekin

117 papers receiving 5.5k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2019 Journal of Clinical Oncology
2009 Journal of Clinical Oncology
2008 Gynecologic Oncology

Peers

Countries citing papers authored by D. Scott McMeekin

Since Specialization

Citations

This map shows the geographic impact of D. Scott McMeekin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Scott McMeekin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Scott McMeekin more than expected).

Fields of papers citing papers by D. Scott McMeekin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Scott McMeekin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Scott McMeekin. The network helps show where D. Scott McMeekin may publish in the future.

Co-authorship network

The 25 scholars most cited alongside D. Scott McMeekin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with D. Scott McMeekin Line = papers co-authored together D. Scott McMeekin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancerbreakdown → Journal of Clinical Oncology ·Marcus E. Randall,Virginia L. Filiaci,D. Scott McMeekin,Vivian von Gruenigen,Helen Huang,Catheryn M. Yashar,Robert S. Mannel,Jae‐Weon Kim,Ritu Salani,Paul DiSilvestro,James J. Burke,Thomas Rutherford,Nick M. Spirtos,Keith Y. Terada,Penny R. Anderson,Wendy R. Brewster,William Small,Carol Aghajanian,David S. Miller	2019	209
2	The pro-inflammatory effect of obesity on high grade serous ovarian cancer Gynecologic Oncology ·Camille C. Gunderson,Kai Ding,Justin Dvorak,Kathleen N. Moore,D. Scott McMeekin,Doris M. Benbrook	2016	6
3	Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial Obstetrical & Gynecological Survey ·Ashley S. Felix,Louise A. Brinton,D. Scott McMeekin,William T. Creasman,David G. Mutch,David E. Cohn,Joan L. Walker,Richard G. Moore,Levi S. Downs,Robert A. Soslow,Richard J. Zaino,Mark E. Sherman	2015	2
4	A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies Cancer Chemotherapy and Pharmacology ·Stephen K. Williamson,Gary A. Johnson,Holly Maulhardt,Kathleen N. Moore,D. Scott McMeekin,Thomas K. Schulz,Gregory A. Reed,Katherine F. Roby,Christine B. Mackay,H. John Smith,Scott J. Weir,Jo Wick,Maurie Markman,Gere S. diZerega,Michael Baltezor,Jahna Espinosa,Charles J. Decedue	2015	52
5	Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors Gynecologic Oncology ·Lisa M. Landrum,Elizabeth Nugent,Rosemary E. Zuna,Elizabeth Syzek,Robert S. Mannel,Kathleen N. Moore,Joan L. Walker,D. Scott McMeekin	2013	29
6	Distance Traveled for Treatment of Cervical Cancer International Journal of Gynecological Cancer ·Camille C. Gunderson,Elizabeth Nugent,D. Scott McMeekin,Kathleen N. Moore	2013	31
7	Uterine Serous Carcinoma: Increased Familial Risk for Lynch-Associated Malignancies Cancer Prevention Research ·Summer Dewdney,Nora T. Kizer,Abegail A. Andaya,Sheri A. Babb,Jingqin Luo,David G. Mutch,Amy P. Schmidt,Louise A. Brinton,Russell R. Broaddus,Nilsa C. Ramirez,Phyllis C. Huettner,D. Scott McMeekin,Kathleen M. Darcy,Shamshad Ali,Patricia L. Judson,Robert S. Mannel,Shashikant B. Lele,David M. O’Malley,Paul J. Goodfellow	2012	17
8	Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study Journal of Clinical Oncology ·Carol Aghajanian,Michael W. Sill,Kathleen M. Darcy,Benjamin E. Greer,D. Scott McMeekin,Peter G. Rose,Jacob Rotmensch,Mack N. Barnes,Parviz Hanjani,Kimberly K. Leslie	2011	214
9	A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study Gynecologic Oncology ·Robert L. Coleman,William E. Brady,D. Scott McMeekin,Peter G. Rose,John T. Soper,Samuel S. Lentz,James Hoffman,Mark S. Shahin	2011	88
10	Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study Gynecologic Oncology ·Alessandro D. Santin,Michael W. Sill,D. Scott McMeekin,Mario M. Leitão,Jubilee Brown,Gregory P. Sutton,Linda Van Le,Patricia Griffin,Cecelia H. Boardman	2011	82
11	Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: A Gynecologic Oncology Group study Gynecologic Oncology ·David Cella,Helen Huang,Bradley J. Monk,Lari Wenzel,J Bénda,D. Scott McMeekin,David E. Cohn,Lois M. Ramondetta,Cecelia H. Boardman	2010	27
12	Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study Gynecologic Oncology ·Gini F. Fleming,Michael W. Sill,Kathleen M. Darcy,D. Scott McMeekin,J.T. Thigpen,Lisa Adler,Jonathan S. Berek,Julia Chapman,Paul DiSilvestro,Ira Horowitz,James V. Fiorica	2009	200
13	Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: Results of a multicenter phase II study Gynecologic Oncology ·D. Scott McMeekin,Alla Lisyanskaya,Marta A. Crispens,Amit M. Oza,Patricia S. Braly,David L. Doering,Eliel Bayever,B. Michiels,Maurie Markman	2009	16
14	Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: A Gynecologic Oncology Group study Gynecologic Oncology ·D. Scott McMeekin,Joan L. Walker,Ellen M. Hartenbach,Michael A. Bookman,Wui-Jin Koh	2008	6
15	A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens British Journal of Cancer ·(unknown),Carolyn Krasner,D. Scott McMeekin,Stephen Chan,Patricia S. Braly,Frank Gary Renshaw,Stan B. Kaye,Diane Provencher,S. M. Campos,Martin Gore	2007	85
16	The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: A Gynecologic Oncology Group study Gynecologic Oncology ·D. Scott McMeekin,Virginia L. Filiaci,J.T. Thigpen,Holly H. Gallion,Gini F. Fleming,William H. Rodgers	2007	110
17	Preoperative predictors of positive margins after loop electrosurgical excisional procedure–Cone Gynecologic Oncology ·Todd Tillmanns,Camille A. Falkner,David B. Engle,Jim Y. Wan,Robert S. Mannel,Joan L. Walker,Gary A. Johnson,D. Scott McMeekin,Rosemarry Zuna,Michael A. Gold	2005	21
18	Surgical–pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecologic Oncology ·Scott Kamelle,Teresa Rutledge,Todd Tillmanns,Natalie S. Gould,David E. Cohn,Jason D. Wright,Thomas J. Herzog,Janet S. Rader,Michael A. Gold,Gary A. Johnson,Joan L. Walker,Robert S. Mannel,D. Scott McMeekin	2004	26
19	A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer Gynecologic Oncology ·D. Scott McMeekin,Alan N. Gordon,Jeffrey M. Fowler,Allen S. Melemed,Richard E. Buller,Thomas J. Burke,J. Bloss,Paul Sabbatini	2003	55
20	Laparoscopic Pelvic and Paraaortic Lymph Node Dissection in the Obese Gynecologic Oncology ·Dennis R. Scribner,Joan L. Walker,Gary A. Johnson,D. Scott McMeekin,Michael A. Gold,Robert S. Mannel	2002	87

About D. Scott McMeekin

D. Scott McMeekin is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Oncology, having authored 121 papers that have together received 5.6k indexed citations. Recurring topics across this work include Endometrial and Cervical Cancer Treatments (73 papers), Ovarian cancer diagnosis and treatment (69 papers), Endometriosis Research and Treatment (19 papers), Cervical Cancer and HPV Research (15 papers), Intraperitoneal and Appendiceal Malignancies (14 papers), Uterine Myomas and Treatments (13 papers), Colorectal and Anal Carcinomas (8 papers) and Estrogen and related hormone effects (8 papers). The work is most often cited by research in Obstetrics and Gynecology (3.3k citations), Reproductive Medicine (2.8k citations) and Oncology (1.3k citations). D. Scott McMeekin has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Michael W. Sill, Paul DiSilvestro, J Bénda, David E. Cohn, Joan L. Walker, Robert S. Mannel, Kathleen N. Moore, Michael A. Gold, Richard G. Moore and Bradley J. Monk. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact